Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

Kochi University

Status: Completed

Conditions: Liver Cancer

Treatments: Drug: LIVACT

Study type: Interventional

Funder types: Other

Identifiers

NCT01434524

LIVACT 0801 (Other Identifier)

Details and patient eligibility

About

The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.

Full description

This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.

Enrollment: 56 patients

Sex: All

Ages: 16 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• These patients were scheduled for elective liver resection to treat hepatocellular carcinoma or adenocarcinoma of the liver.

Exclusion criteria

• a body-weight loss greater than 10% during the 6 months prior to surgery,
• the presence of distant metastases, or
• serious impairment of organ function due to respiratory, renal, or heart disease.

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

56 participants in 2 patient groups

Control

No Intervention group

Description:

normal dietary

LIVACT

No Intervention group

Description:

The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.

Treatment:

Drug: LIVACT